1. de Wit, E., van Doremalen, N., Falzarano, D. & Munster, V. J. SARS and MERS: recent insights into emerging coronaviruses. Nat. Rev. Microbiol. 14, 523-534 (2016). [OpenAIRE]
2. Li, Q. et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N. Engl. J. Med. 382, 1199-1207 (2020).
3. Callaway, E., Cyranoski, D., Mallapaty, S., Stoye, E. & Tollefson, J. eTh coronavirus pandemic in vfie powerful charts. Nature (2020).
4. Li, G. & De Clercq, E. eThrapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat. Rev. Drug Discov. 19, 149-150 (2020).
5. Cheng, Y.-S., Williamson, P. R. & Zheng, W. Improving therapy of severe infections through drug repurposing of synergistic combinations. Curr. Opin. Pharmacol. 48, 92-98 (2019).
6. Manganaro, R. et al. Synthesis and antiviral eefct of novel ufloxetine analogues as enterovirus 2C inhibitors. Antiviral Res. 178, 104781 (2020).
7. de Wilde, A. H. et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob. Agents Chemother. 58, 4875-4884 (2014).
8. Dyall, J. et al. Repurposing of clinically developed drugs for treatment of middle east respiratory syndrome coronavirus infection. Antimicrob. Agents Chemother. 58, 4885-4893 (2014).
9. Mercorelli, B., Palù, G. & Loregian, A. Drug repurposing for viral infectious diseases: how far are we?. Trends Microbiol. 26, 865-876 (2018). [OpenAIRE]
10. Delang, L. et al. eTh viral capping enzyme nsP1: a novel target for the inhibition of chikungunya virus infection. Sci. Rep. 6, 31819 (2016).
11. Touret, F. et al. Phylogenetically based establishment of a dengue virus panel, representing all available genotypes, as a tool in dengue drug discovery. Antiviral Res. 168, 109-113 (2019). [OpenAIRE]
12. Blaising, J., Polyak, S. J. & Pécheur, E.-I. Arbidol as a broad-spectrum antiviral: an update. Antiviral Res. 107, 84-94 (2014). [OpenAIRE]
13. Liu, J. et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is eefctive in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 6, 16 (2020).
14. Wang, M. et al. Remdesivir and chloroquine eefctively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 1, 1-3 (2020).
15. Yao, X. et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis. (2020).